Innova CaptabQ1 FY25

Innova Captab Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,037.7P/E: 35.6Market Cap: ₹5.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • The company expects to maintain a strong growth trajectory, aiming to double revenue and bottom-line over the next 3-4 years, driven primarily by the new Jammu facility.
  • Jammu plant is projected to generate Rs 800-900 crores of sales in 3-4 years, with revenue start anticipated from Q3 FY25.
  • The Jammu facility is expected to deliver better-than-Rs 200-300 crores revenue in FY25.
  • Regular business (excluding Jammu) is expected to grow in the early teens percentage range due to capacity constraints.
  • Overall blended growth for the current year is estimated between 12%-15%, with margins expected to remain at similar levels.
  • Trade generics business aims to double within 3 years, maintaining its current ~17% share.
  • Expansion of product categories and R&D investment supports long-term volume and revenue growth.

See what Innova Captab management said on margin guidance — free account, 30 seconds.

Fundraise plans

The provided transcript does not explicitly mention any current or future plans for fundraising through debt or equity by Innova Captab Limited. Key points related to financial plans include: - Capex guidance focuses primarily on the new R&D plant in Panchkula with Rs 10-15 crores expenditure this year. - Jammu facility capex is mostly completed; future capex limited to 3-4% maintenance until new manufacturing facilities are planned. - No explicit mention of plans for raising funds via debt or equity. - Company expects to fund growth from existing operations and capital investments without indicating external fundraising. Therefore, as per the available information, there is no indication of current or upcoming fundraising through debt or equity.

See what Innova Captab management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The R&D capex for the new R&D center in Panchkula, Haryana, is already committed with an expenditure of Rs 10-15 crores expected this year.
  • The Jammu facility's major capex is mostly completed with about Rs 450 crores invested so far.
  • Future capex, apart from maintenance, will only be undertaken when planning for a new manufacturing facility; currently, maintenance capex is estimated at 3-4% of the gross block.
  • The Jammu greenfield expansion is progressing as planned, expected to commercialize in Q2 FY25, with revenue starting from Q3 FY25.
  • Jammu unit will have four independent manufacturing blocks, enhancing the product portfolio and capacity.
  • Long-term, the Jammu plant has asset potential to generate up to Rs 2,000 crores in topline at 40-50% utilization, targeting Rs 800-900 crores in 3-4 years.
  • No additional major capex is planned until the next facility is announced.

Track Innova Captab — get its next earnings analysis in your feed

How does Innova Captab rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisInnova Captab
Rev 2Mar 3

How does Innova Captab rank in Pharmaceuticals & Biotechnology?

Compare Innova Captab against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →